HPV Vaccines Market: By Product Type (Bivalent, Polyvalent, Others) By Disease Indication (HPV Associated Cancer, Genital Warts, Others) By End User (Hospitals & Retail Pharmacies, Government Suppliers, Others), and Geography  

HPV Vaccines Market size was valued at USD 4,867.9 million in 2022 and is poised to grow at a CAGR of 5.3% from 2023-2029. Vaccines against the human papillomavirus (HPV) are designed to protect against infection with specific HPV strains. There are HPV vaccines that offer protection against two, four, or nine different forms of HPV. The HPV types 16 and 18, which carry the highest risk of cervical cancer, are at least protected against by all HPV vaccinations. According to estimates, HPV vaccinations can prevent over 90% of HPV-positive oropharyngeal cancers and may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, and 40% of vulvar cancer. Additionally, they can prevent some genital warts; the greatest protection is provided by the quadrivalent and nonavalent vaccines against HPV strains HPV-6 and HPV-11. Higher demand for an effective vaccine, growing investments in research and development, increase in the number of HPV cases act as the drivers boosting the global market. A few restraints include imposing stringent policies for supplying vaccines and limited availability of medicine. The introduction of novel immunization remedies provides multiple opportunities to the global HPV vaccine market.